SlideShare une entreprise Scribd logo
1  sur  1
Télécharger pour lire hors ligne
Artificial Intelligence, System Analysis and Simulation Modeling
in Optimization of Management for Lung Cancer Patients
Oleg Kshivets, MD, PhD Surgery Department, Khimki Clinic N1, Moscow, Russia PS-01.40
OBJECTIVE: Search of best management for non-small lung cancer (LC) patients (LCP) (T1-4N0-2M0) was realized.
METHODS: We analyzed data of 672 consecutive LCP (age=57.5±8.3 years; tumor size=4.4±2.4 cm) radically operated and
monitored in 1985-2016 (m=581, f=91; lobectomies=430, pneumonectomies=242, combined procedures with resection of trachea,
carina, atrium, aorta, VCS, vena azygos, pericardium, liver, diaphragm, ribs, esophagus=184; only surgery=530, adjuvant
chemoimmunoradiotherapy-AT=142: CAV/gemzar + cisplatin + thymalin/taktivin + radiotherapy 45-50Gy; T1=239, T2=249, T3=129,
T4=55; N0=425, N1=130, N2=117, M0=672; G1=168, G2=201, G3=303; squamous=380, adenocarcinoma=247, large cell=45; early
LC=134, invasive LC=538. Multivariate Cox modeling, clustering, SEPATH, Monte Carlo, bootstrap and neural networks computing
were used to determine any significant dependence.
RESULTS: Overall life span (LS) was 2104.2±1685.2 days and cumulative 5-year survival (5YS) reached 69.7%, 10 years – 61.9%,
20 years – 42.5%. 417 LCP lived more than 5 years (LS=3044.7±1472.2 days), 109 LCP – more than 10 years (LS=5048±1471.6 days).
194 LCP died because of LC (LS=560.7±372.9 days). AT significantly improved 5YS (65.3% vs. 34.3%) (P=0.00001 by log-rank test)
only for LCP with N1-2. Cox modeling displayed (Chi2=292.44, df=13, P=0.000) that 5YS of LCP significantly depended on: phase
transition (PT)“early-invasive LC” in terms of synergetics, PT N0-N12, histology, G, blood cell subpopulations, cell ratio factors
(ratio between blood cells subpopulations and cancer cells-CC), prothrombin index, heparin tolerance, recalcification time,
glucose, AT (P=0.000-0.033). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between
5YS and PT“early-invasive LC” (rank=1), PT N0-N12 (rank=2), AT (3), segmented neutrophils (4), lymphocytes (5), prothrombin
index (6),healthy cells/CC (7), T1-4 (8), tumor size (9), thrombocytes/CC (10), erythrocytes/CC (11),lymphocytes/CC (12). Correct
prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
CONCLUSIONS: Optimal management for LCP are: 1) screening and early detection of LC; 2) availability of experienced thoracic
surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for
completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Parameter Estimates:Chi2=292.44, df=13, P=0.0000, n=672
Cox Regression Parameter
Estimate
Standard
Error
Chi-
square
P value 95%
Lower CL
95%
Upper CL
Hazard
Ratio
95%
HazardRatio
Lower CL
95%
HazardRatio
Upper CL
Histology 0.29021 0.087856 10.91150 0.000956 0.11802 0.462408 1.336711 1.125263 1.587893
G1-3 0.32570 0.089528 13.23471 0.000275 0.15023 0.501169 1.384997 1.162098 1.650649
Phase Transition Early-Invasive Cancer -1.32520 0.393120 11.36353 0.000749 -2.09570 -0.554700 0.265749 0.122984 0.574244
Adjuvant Chemoimmunoradiotherapy -1.01228 0.201036 25.35421 0.000000 -1.40630 -0.618253 0.363391 0.245048 0.538885
Phase Transition N0--N12 1.06470 0.147841 51.86362 0.000000 0.77493 1.354459 2.899959 2.170449 3.874666
Glucose -0.29033 0.081154 12.79817 0.000347 -0.44938 -0.131266 0.748020 0.638020 0.876984
Prothrombin Index 0.03002 0.006828 19.32862 0.000011 0.01664 0.043400 1.030473 1.016775 1.044356
Recalcification Time -0.00585 0.001771 10.92016 0.000951 -0.00932 -0.002381 0.994166 0.990722 0.997622
Heparin Tolerance 0.00366 0.000667 30.07778 0.000000 0.00235 0.004965 1.003665 1.002353 1.004977
Eosinophils/Cancer Cells -0.99120 0.425130 5.43595 0.019726 -1.82443 -0.157957 0.371133 0.161309 0.853887
Lymphocytes/Cancer Cells -0.17877 0.067403 7.03422 0.007997 -0.31088 -0.046660 0.836300 0.732805 0.954412
Erythrocytes (tot) -0.03803 0.017819 4.55381 0.032846 -0.07295 -0.003101 0.962688 0.929647 0.996904
Thrombocytes (tot) 0.00050 0.000191 6.81611 0.009034 0.00012 0.000872 1.000498 1.000124 1.000872
Neural Networks: n=611
Baseline Error=0.000;
Area under ROC Curve=1.000;
Correct Classification Rate=100%
Rank Sensitivity
PT Early---Invasive Cancer 1 9516
PT N0---N12 2 9479
Adjuvant Chemoimmunoradiotherapy 3 6705
Segmented Neutrophils 4 5951
Lymphocytes 5 5894
Prothrombin Index 6 5126
Healthy Cells/Cancer Cells 7 5034
T1-4 8 4255
Tumor Size 9 3525
Thrombocytes/Cancer Cells 10 2840
Erythrocytes/Cancer Cells 11 2740
Lymphocytes/Cancer Cells 12 2170
Bootstrap Simulation Rank Kendall’Tau-A P<
Lymphocytes/Cancer Cells 1 -0.227 0.000
Healthy Cells/Cancer Cells 2 -0.223 0.000
Erythrocytes/Cancer Cells 3 -0.221 0.000
PT N0---N12 4 0.197 0.000
Thrombocytes/Cancer Cells 5 -0.197 0.000
Leucocytes/Cancer Cells 6 -0.188 0.000
Prothrombin Index 7 0.163 0.000
Eosinophils/Cancer Cells 8 -0.161 0.000
Monocytes/Cancer Cells 9 -0.144 0.000
Tumor Size 10 0.143 0.000
Seg.Neutrophils/Cancer Cells 11 -0.134 0.000
PT Early---Invasive Cancer 12 -0.131 0.000
T1-4 13 -0.124 0.000
Lymphocytes (tot) 14 -0.108 0.000
Erythrocytes (tot) 15 -0.117 0.000
Segmented Neutrophils (%) 16 0.109 0.000
Weight 17 -0.105 0.000
Eosinophils (tot) 18 -0.085 0.01
Lymphocytes (%) 19 -0.086 0.01
G1-3 20 0.083 0.01
ESS 21 0.082 0.01
Lymphocytes (abs) 22 -0.082 0.01
Heparin Tolerance 23 0.078 0.01
Stick Neutrophils/Cancer Cells 24 -0.077 0.01
Glucose 25 -0.072 0.01
Only Surgery 26 -0.065 0.05
Eosinophils (%) 27 -0.063 0.05
Eosinophils (abs) 28 -0.059 0.05
0 5 10
15
20
25
30
35
Lymphocytes/Cancer Cells
11.11.21.31.41.51.61.71.81.9
PT Early--Invasive Cancer
1
1
1.1
1.1
1.2
1.2
1.3
1.3
1.4
1.4
1.5
1.5
1.6
1.6
1.7
1.7
1.8
1.8
1.9
1.9
2
2
5-YearSurvival
5-YearSurvival
P=0.0000
z=a+blnx+cy+d(lnx)^2+ey^2+fylnx+g(lnx)^3+hy^3+iy^2lnx+jy(lnx)^2
r^2=0.15389193 DF Adj r^2=0.13979013 FitStdErr=0.43174167 Fstat=12.145684
a=1.6730247 b=0.10714131 c=-1.559062 d=-0.054738649 e=2.0848282
f=-0.42449195 g=0.0015228759 h=-0.73551088 i=0.18814164 j=0.022282855
0 5 10 15 20 25 30 35
Lymphocytes/Cancer Cells
00.10.20.30.40.50.60.70.80.9
PT N0---N12
1
1
1.1
1.1
1.2
1.2
1.3
1.3
1.4
1.4
1.5
1.5
1.6
1.6
1.7
1.7
1.8
1.8
1.9
1.9
2
2
5-YearSurvival
5-YearSurvival
P=0.0000
z=a+b/x+c/x^2+d/x^3+e/x^4+f/x^5+gy
r^2=0.24088672 DF Adj r^2=0.23207446 FitStdErr=0.40792762 Fstat=31.944196
a=0.85682428 b=1.0401408 c=-1.0202475 d=0.47891711
e=-0.098874149 f=0.0071729116 g=0.37035265

Contenu connexe

Tendances

Kshivets O. Cardioesophageal Cancer Surgery
Kshivets O. Cardioesophageal Cancer SurgeryKshivets O. Cardioesophageal Cancer Surgery
Kshivets O. Cardioesophageal Cancer SurgeryOleg Kshivets
 
Kshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryKshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryOleg Kshivets
 
Kshivets O. Lung Cancer Surgery: Prognosis
Kshivets O. Lung Cancer Surgery: PrognosisKshivets O. Lung Cancer Surgery: Prognosis
Kshivets O. Lung Cancer Surgery: PrognosisOleg Kshivets
 
Kshivets O. Esophageal and Cardioesophageal Cancer Surgery
Kshivets O. Esophageal and Cardioesophageal Cancer SurgeryKshivets O. Esophageal and Cardioesophageal Cancer Surgery
Kshivets O. Esophageal and Cardioesophageal Cancer SurgeryOleg Kshivets
 
Kshivets O. Lung Cancer Surgery: Synergetics and Prediction
Kshivets O. Lung Cancer Surgery: Synergetics and PredictionKshivets O. Lung Cancer Surgery: Synergetics and Prediction
Kshivets O. Lung Cancer Surgery: Synergetics and PredictionOleg Kshivets
 
2021 esmo world_gi_poster_kshivets
2021 esmo world_gi_poster_kshivets2021 esmo world_gi_poster_kshivets
2021 esmo world_gi_poster_kshivetsOleg Kshivets
 
Kshivets barcelona2019
Kshivets barcelona2019Kshivets barcelona2019
Kshivets barcelona2019Oleg Kshivets
 
Kshivets O. Esophageal Cancer Surgery
Kshivets O.  Esophageal Cancer SurgeryKshivets O.  Esophageal Cancer Surgery
Kshivets O. Esophageal Cancer SurgeryOleg Kshivets
 
Kshivets wscts2019 sofia
Kshivets wscts2019 sofiaKshivets wscts2019 sofia
Kshivets wscts2019 sofiaOleg Kshivets
 
Kshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryKshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryOleg Kshivets
 
Lung Cancer: 10-Year Survival
Lung Cancer: 10-Year Survival           Lung Cancer: 10-Year Survival
Lung Cancer: 10-Year Survival Oleg Kshivets
 
Kshivets IASLC_Vienna2016
Kshivets IASLC_Vienna2016Kshivets IASLC_Vienna2016
Kshivets IASLC_Vienna2016Oleg Kshivets
 
Kshivets O. Cancer, Computer Sciences and Alive Supersystems
Kshivets O. Cancer, Computer Sciences and Alive SupersystemsKshivets O. Cancer, Computer Sciences and Alive Supersystems
Kshivets O. Cancer, Computer Sciences and Alive SupersystemsOleg Kshivets
 
Kshivets barcelona2017
Kshivets barcelona2017Kshivets barcelona2017
Kshivets barcelona2017Oleg Kshivets
 
Kshivets eacts milan2018
Kshivets eacts milan2018Kshivets eacts milan2018
Kshivets eacts milan2018Oleg Kshivets
 
Kshivets O. Lung Cancer: Early Detection and Diagnosis
Kshivets O. Lung Cancer: Early Detection and Diagnosis Kshivets O. Lung Cancer: Early Detection and Diagnosis
Kshivets O. Lung Cancer: Early Detection and Diagnosis Oleg Kshivets
 
PRECISE EARLY DETECTION OF LUNG CANCER AND IMMUNE CIRCUIT
PRECISE EARLY DETECTION OF LUNG  CANCER AND IMMUNE CIRCUITPRECISE EARLY DETECTION OF LUNG  CANCER AND IMMUNE CIRCUIT
PRECISE EARLY DETECTION OF LUNG CANCER AND IMMUNE CIRCUITOleg Kshivets
 
Kshivets barcelona2016
Kshivets barcelona2016Kshivets barcelona2016
Kshivets barcelona2016Oleg Kshivets
 

Tendances (20)

Kshivets O. Cardioesophageal Cancer Surgery
Kshivets O. Cardioesophageal Cancer SurgeryKshivets O. Cardioesophageal Cancer Surgery
Kshivets O. Cardioesophageal Cancer Surgery
 
Kshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryKshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer Surgery
 
Kshivets O. Lung Cancer Surgery: Prognosis
Kshivets O. Lung Cancer Surgery: PrognosisKshivets O. Lung Cancer Surgery: Prognosis
Kshivets O. Lung Cancer Surgery: Prognosis
 
Kshivets O. Esophageal and Cardioesophageal Cancer Surgery
Kshivets O. Esophageal and Cardioesophageal Cancer SurgeryKshivets O. Esophageal and Cardioesophageal Cancer Surgery
Kshivets O. Esophageal and Cardioesophageal Cancer Surgery
 
Kshivets O. Lung Cancer Surgery: Synergetics and Prediction
Kshivets O. Lung Cancer Surgery: Synergetics and PredictionKshivets O. Lung Cancer Surgery: Synergetics and Prediction
Kshivets O. Lung Cancer Surgery: Synergetics and Prediction
 
2021 esmo world_gi_poster_kshivets
2021 esmo world_gi_poster_kshivets2021 esmo world_gi_poster_kshivets
2021 esmo world_gi_poster_kshivets
 
Kshivets barcelona2019
Kshivets barcelona2019Kshivets barcelona2019
Kshivets barcelona2019
 
Kshivets O. Esophageal Cancer Surgery
Kshivets O.  Esophageal Cancer SurgeryKshivets O.  Esophageal Cancer Surgery
Kshivets O. Esophageal Cancer Surgery
 
Kshivets sso2013
Kshivets sso2013Kshivets sso2013
Kshivets sso2013
 
Kshivets wscts2019 sofia
Kshivets wscts2019 sofiaKshivets wscts2019 sofia
Kshivets wscts2019 sofia
 
Kshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryKshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer Surgery
 
Lung Cancer: 10-Year Survival
Lung Cancer: 10-Year Survival           Lung Cancer: 10-Year Survival
Lung Cancer: 10-Year Survival
 
Kshivets IASLC_Vienna2016
Kshivets IASLC_Vienna2016Kshivets IASLC_Vienna2016
Kshivets IASLC_Vienna2016
 
Kshivets O. Cancer, Computer Sciences and Alive Supersystems
Kshivets O. Cancer, Computer Sciences and Alive SupersystemsKshivets O. Cancer, Computer Sciences and Alive Supersystems
Kshivets O. Cancer, Computer Sciences and Alive Supersystems
 
Kshivets barcelona2017
Kshivets barcelona2017Kshivets barcelona2017
Kshivets barcelona2017
 
Kshivets elcc2022
Kshivets elcc2022Kshivets elcc2022
Kshivets elcc2022
 
Kshivets eacts milan2018
Kshivets eacts milan2018Kshivets eacts milan2018
Kshivets eacts milan2018
 
Kshivets O. Lung Cancer: Early Detection and Diagnosis
Kshivets O. Lung Cancer: Early Detection and Diagnosis Kshivets O. Lung Cancer: Early Detection and Diagnosis
Kshivets O. Lung Cancer: Early Detection and Diagnosis
 
PRECISE EARLY DETECTION OF LUNG CANCER AND IMMUNE CIRCUIT
PRECISE EARLY DETECTION OF LUNG  CANCER AND IMMUNE CIRCUITPRECISE EARLY DETECTION OF LUNG  CANCER AND IMMUNE CIRCUIT
PRECISE EARLY DETECTION OF LUNG CANCER AND IMMUNE CIRCUIT
 
Kshivets barcelona2016
Kshivets barcelona2016Kshivets barcelona2016
Kshivets barcelona2016
 

En vedette

Kshivets O. Synergetics and Survival of Lung Cancer Patients
Kshivets O. Synergetics and Survival of Lung Cancer PatientsKshivets O. Synergetics and Survival of Lung Cancer Patients
Kshivets O. Synergetics and Survival of Lung Cancer PatientsOleg Kshivets
 
Kshivets O. Expert Systems for Diagnosis and Prognosis of Malignant Neoplasms
Kshivets O. Expert Systems for Diagnosis and Prognosis of Malignant NeoplasmsKshivets O. Expert Systems for Diagnosis and Prognosis of Malignant Neoplasms
Kshivets O. Expert Systems for Diagnosis and Prognosis of Malignant NeoplasmsOleg Kshivets
 
Kshivets O. Esophageal & Cardioesophageal Surgery
Kshivets O. Esophageal & Cardioesophageal SurgeryKshivets O. Esophageal & Cardioesophageal Surgery
Kshivets O. Esophageal & Cardioesophageal SurgeryOleg Kshivets
 
Kshivets O. Cancer, Synergetics, Computer Sciences and Alive Supersystems
Kshivets O. Cancer, Synergetics, Computer Sciences and Alive SupersystemsKshivets O. Cancer, Synergetics, Computer Sciences and Alive Supersystems
Kshivets O. Cancer, Synergetics, Computer Sciences and Alive SupersystemsOleg Kshivets
 
Kshivets O. Cancer, Synergetics and Immune Circuit
Kshivets O.   Cancer, Synergetics and Immune CircuitKshivets O.   Cancer, Synergetics and Immune Circuit
Kshivets O. Cancer, Synergetics and Immune CircuitOleg Kshivets
 

En vedette (7)

Kshivets O. Synergetics and Survival of Lung Cancer Patients
Kshivets O. Synergetics and Survival of Lung Cancer PatientsKshivets O. Synergetics and Survival of Lung Cancer Patients
Kshivets O. Synergetics and Survival of Lung Cancer Patients
 
Kshivets O. Expert Systems for Diagnosis and Prognosis of Malignant Neoplasms
Kshivets O. Expert Systems for Diagnosis and Prognosis of Malignant NeoplasmsKshivets O. Expert Systems for Diagnosis and Prognosis of Malignant Neoplasms
Kshivets O. Expert Systems for Diagnosis and Prognosis of Malignant Neoplasms
 
Kshivets O. Esophageal & Cardioesophageal Surgery
Kshivets O. Esophageal & Cardioesophageal SurgeryKshivets O. Esophageal & Cardioesophageal Surgery
Kshivets O. Esophageal & Cardioesophageal Surgery
 
Kshivets O. Cancer, Synergetics, Computer Sciences and Alive Supersystems
Kshivets O. Cancer, Synergetics, Computer Sciences and Alive SupersystemsKshivets O. Cancer, Synergetics, Computer Sciences and Alive Supersystems
Kshivets O. Cancer, Synergetics, Computer Sciences and Alive Supersystems
 
Kshivets wscts2015
Kshivets wscts2015Kshivets wscts2015
Kshivets wscts2015
 
Kshivets O. Cancer, Synergetics and Immune Circuit
Kshivets O.   Cancer, Synergetics and Immune CircuitKshivets O.   Cancer, Synergetics and Immune Circuit
Kshivets O. Cancer, Synergetics and Immune Circuit
 
Kshivets milan2014
Kshivets milan2014Kshivets milan2014
Kshivets milan2014
 

Similaire à Kshivets chicago2016

Kshivets_SPB_WSCTS2022Lung.pdf
Kshivets_SPB_WSCTS2022Lung.pdfKshivets_SPB_WSCTS2022Lung.pdf
Kshivets_SPB_WSCTS2022Lung.pdfOleg Kshivets
 
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...Oleg Kshivets
 
Kshivets barcelona2020
Kshivets barcelona2020Kshivets barcelona2020
Kshivets barcelona2020Oleg Kshivets
 
Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...
Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...
Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...Oleg Kshivets
 
Kshivets_SPB_WSCTS2022Eso.pdf
Kshivets_SPB_WSCTS2022Eso.pdfKshivets_SPB_WSCTS2022Eso.pdf
Kshivets_SPB_WSCTS2022Eso.pdfOleg Kshivets
 
Esophageal Cancer: Precise Prediction
Esophageal Cancer: Precise Prediction      Esophageal Cancer: Precise Prediction
Esophageal Cancer: Precise Prediction Oleg Kshivets
 
Kshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryKshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryOleg Kshivets
 
Kshivets_IASLC_Singapore2023.pdf
Kshivets_IASLC_Singapore2023.pdfKshivets_IASLC_Singapore2023.pdf
Kshivets_IASLC_Singapore2023.pdfOleg Kshivets
 
Kshivets O. Local Advanced Lung Cancer Surgery
Kshivets O. Local Advanced Lung Cancer Surgery Kshivets O. Local Advanced Lung Cancer Surgery
Kshivets O. Local Advanced Lung Cancer Surgery Oleg Kshivets
 
Immunotherapy innsclc2017 thoracicsurgeons
Immunotherapy innsclc2017 thoracicsurgeonsImmunotherapy innsclc2017 thoracicsurgeons
Immunotherapy innsclc2017 thoracicsurgeonsMauricio Lema
 
Integración de la inmunoterapia en NSCLC
Integración de la inmunoterapia en NSCLCIntegración de la inmunoterapia en NSCLC
Integración de la inmunoterapia en NSCLCMauricio Lema
 
Elderly Acute Myeloid Leukemia
Elderly Acute Myeloid LeukemiaElderly Acute Myeloid Leukemia
Elderly Acute Myeloid Leukemiaspa718
 
Kshivets Oleg Local Advanced Gastric Cancer: Optimization of Management
Kshivets Oleg Local Advanced Gastric Cancer: Optimization of ManagementKshivets Oleg Local Advanced Gastric Cancer: Optimization of Management
Kshivets Oleg Local Advanced Gastric Cancer: Optimization of ManagementOleg Kshivets
 
4-yr OS after 2nd-line Nivolumab, pooled analysis (based on Scott Antonia pre...
4-yr OS after 2nd-line Nivolumab, pooled analysis (based on Scott Antonia pre...4-yr OS after 2nd-line Nivolumab, pooled analysis (based on Scott Antonia pre...
4-yr OS after 2nd-line Nivolumab, pooled analysis (based on Scott Antonia pre...Mauricio Lema
 
CCO_Biomarkers_Lung_Cancer_ASCO_Slides_2.pptx
CCO_Biomarkers_Lung_Cancer_ASCO_Slides_2.pptxCCO_Biomarkers_Lung_Cancer_ASCO_Slides_2.pptx
CCO_Biomarkers_Lung_Cancer_ASCO_Slides_2.pptxPeterpanNguyen
 

Similaire à Kshivets chicago2016 (17)

Kshivets_SPB_WSCTS2022Lung.pdf
Kshivets_SPB_WSCTS2022Lung.pdfKshivets_SPB_WSCTS2022Lung.pdf
Kshivets_SPB_WSCTS2022Lung.pdf
 
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
 
Kshivets barcelona2020
Kshivets barcelona2020Kshivets barcelona2020
Kshivets barcelona2020
 
Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...
Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...
Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...
 
Kshivets_SPB_WSCTS2022Eso.pdf
Kshivets_SPB_WSCTS2022Eso.pdfKshivets_SPB_WSCTS2022Eso.pdf
Kshivets_SPB_WSCTS2022Eso.pdf
 
Esophageal Cancer: Precise Prediction
Esophageal Cancer: Precise Prediction      Esophageal Cancer: Precise Prediction
Esophageal Cancer: Precise Prediction
 
Kshivets ny2021aats
Kshivets ny2021aatsKshivets ny2021aats
Kshivets ny2021aats
 
Kshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryKshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer Surgery
 
Kshivets_IASLC_Singapore2023.pdf
Kshivets_IASLC_Singapore2023.pdfKshivets_IASLC_Singapore2023.pdf
Kshivets_IASLC_Singapore2023.pdf
 
Kshivets O. Local Advanced Lung Cancer Surgery
Kshivets O. Local Advanced Lung Cancer Surgery Kshivets O. Local Advanced Lung Cancer Surgery
Kshivets O. Local Advanced Lung Cancer Surgery
 
Kshivets esmo2021
Kshivets esmo2021Kshivets esmo2021
Kshivets esmo2021
 
Immunotherapy innsclc2017 thoracicsurgeons
Immunotherapy innsclc2017 thoracicsurgeonsImmunotherapy innsclc2017 thoracicsurgeons
Immunotherapy innsclc2017 thoracicsurgeons
 
Integración de la inmunoterapia en NSCLC
Integración de la inmunoterapia en NSCLCIntegración de la inmunoterapia en NSCLC
Integración de la inmunoterapia en NSCLC
 
Elderly Acute Myeloid Leukemia
Elderly Acute Myeloid LeukemiaElderly Acute Myeloid Leukemia
Elderly Acute Myeloid Leukemia
 
Kshivets Oleg Local Advanced Gastric Cancer: Optimization of Management
Kshivets Oleg Local Advanced Gastric Cancer: Optimization of ManagementKshivets Oleg Local Advanced Gastric Cancer: Optimization of Management
Kshivets Oleg Local Advanced Gastric Cancer: Optimization of Management
 
4-yr OS after 2nd-line Nivolumab, pooled analysis (based on Scott Antonia pre...
4-yr OS after 2nd-line Nivolumab, pooled analysis (based on Scott Antonia pre...4-yr OS after 2nd-line Nivolumab, pooled analysis (based on Scott Antonia pre...
4-yr OS after 2nd-line Nivolumab, pooled analysis (based on Scott Antonia pre...
 
CCO_Biomarkers_Lung_Cancer_ASCO_Slides_2.pptx
CCO_Biomarkers_Lung_Cancer_ASCO_Slides_2.pptxCCO_Biomarkers_Lung_Cancer_ASCO_Slides_2.pptx
CCO_Biomarkers_Lung_Cancer_ASCO_Slides_2.pptx
 

Plus de Oleg Kshivets

KshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdfKshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdfOleg Kshivets
 
Kshivets_WCGIC2023.pdf
Kshivets_WCGIC2023.pdfKshivets_WCGIC2023.pdf
Kshivets_WCGIC2023.pdfOleg Kshivets
 
Kshivets gc 10_ys_wjarr-2021-0659
Kshivets gc 10_ys_wjarr-2021-0659Kshivets gc 10_ys_wjarr-2021-0659
Kshivets gc 10_ys_wjarr-2021-0659Oleg Kshivets
 
Kshivets lc10 ys_wjarr
Kshivets lc10 ys_wjarrKshivets lc10 ys_wjarr
Kshivets lc10 ys_wjarrOleg Kshivets
 
Kshivets eso10 y2021
Kshivets eso10 y2021Kshivets eso10 y2021
Kshivets eso10 y2021Oleg Kshivets
 
Kshivets ASCO Chicago2020
Kshivets ASCO Chicago2020Kshivets ASCO Chicago2020
Kshivets ASCO Chicago2020Oleg Kshivets
 
Kshivets aats new_york2019
Kshivets aats new_york2019Kshivets aats new_york2019
Kshivets aats new_york2019Oleg Kshivets
 
Kshivets aats new_york2018
Kshivets aats new_york2018Kshivets aats new_york2018
Kshivets aats new_york2018Oleg Kshivets
 
Kshivets iaslc toronto2018
Kshivets iaslc toronto2018Kshivets iaslc toronto2018
Kshivets iaslc toronto2018Oleg Kshivets
 

Plus de Oleg Kshivets (10)

KshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdfKshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdf
 
Kshivets_WCGIC2023.pdf
Kshivets_WCGIC2023.pdfKshivets_WCGIC2023.pdf
Kshivets_WCGIC2023.pdf
 
Kshivets gc 10_ys_wjarr-2021-0659
Kshivets gc 10_ys_wjarr-2021-0659Kshivets gc 10_ys_wjarr-2021-0659
Kshivets gc 10_ys_wjarr-2021-0659
 
Kshivets lc10 ys_wjarr
Kshivets lc10 ys_wjarrKshivets lc10 ys_wjarr
Kshivets lc10 ys_wjarr
 
Kshivets eso10 y2021
Kshivets eso10 y2021Kshivets eso10 y2021
Kshivets eso10 y2021
 
Kshivets ASCO Chicago2020
Kshivets ASCO Chicago2020Kshivets ASCO Chicago2020
Kshivets ASCO Chicago2020
 
Kshivets aats new_york2019
Kshivets aats new_york2019Kshivets aats new_york2019
Kshivets aats new_york2019
 
Kshivets IASLC 2019
Kshivets IASLC 2019Kshivets IASLC 2019
Kshivets IASLC 2019
 
Kshivets aats new_york2018
Kshivets aats new_york2018Kshivets aats new_york2018
Kshivets aats new_york2018
 
Kshivets iaslc toronto2018
Kshivets iaslc toronto2018Kshivets iaslc toronto2018
Kshivets iaslc toronto2018
 

Dernier

PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfDolisha Warbi
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptxNIKITA BHUTE
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfHongBiThi1
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectiondrhanifmohdali
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptxWINCY THIRUMURUGAN
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxMAsifAhmad
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfMedicoseAcademics
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptPradnya Wadekar
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Vaikunthan Rajaratnam
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Peter Embi
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.aarjukhadka22
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfHongBiThi1
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...Shubhanshu Gaurav
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .Mohamed Rizk Khodair
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentsaileshpanda05
 

Dernier (20)

PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissection
 
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdf
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.ppt
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing student
 
Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...
 

Kshivets chicago2016

  • 1. Artificial Intelligence, System Analysis and Simulation Modeling in Optimization of Management for Lung Cancer Patients Oleg Kshivets, MD, PhD Surgery Department, Khimki Clinic N1, Moscow, Russia PS-01.40 OBJECTIVE: Search of best management for non-small lung cancer (LC) patients (LCP) (T1-4N0-2M0) was realized. METHODS: We analyzed data of 672 consecutive LCP (age=57.5±8.3 years; tumor size=4.4±2.4 cm) radically operated and monitored in 1985-2016 (m=581, f=91; lobectomies=430, pneumonectomies=242, combined procedures with resection of trachea, carina, atrium, aorta, VCS, vena azygos, pericardium, liver, diaphragm, ribs, esophagus=184; only surgery=530, adjuvant chemoimmunoradiotherapy-AT=142: CAV/gemzar + cisplatin + thymalin/taktivin + radiotherapy 45-50Gy; T1=239, T2=249, T3=129, T4=55; N0=425, N1=130, N2=117, M0=672; G1=168, G2=201, G3=303; squamous=380, adenocarcinoma=247, large cell=45; early LC=134, invasive LC=538. Multivariate Cox modeling, clustering, SEPATH, Monte Carlo, bootstrap and neural networks computing were used to determine any significant dependence. RESULTS: Overall life span (LS) was 2104.2±1685.2 days and cumulative 5-year survival (5YS) reached 69.7%, 10 years – 61.9%, 20 years – 42.5%. 417 LCP lived more than 5 years (LS=3044.7±1472.2 days), 109 LCP – more than 10 years (LS=5048±1471.6 days). 194 LCP died because of LC (LS=560.7±372.9 days). AT significantly improved 5YS (65.3% vs. 34.3%) (P=0.00001 by log-rank test) only for LCP with N1-2. Cox modeling displayed (Chi2=292.44, df=13, P=0.000) that 5YS of LCP significantly depended on: phase transition (PT)“early-invasive LC” in terms of synergetics, PT N0-N12, histology, G, blood cell subpopulations, cell ratio factors (ratio between blood cells subpopulations and cancer cells-CC), prothrombin index, heparin tolerance, recalcification time, glucose, AT (P=0.000-0.033). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT“early-invasive LC” (rank=1), PT N0-N12 (rank=2), AT (3), segmented neutrophils (4), lymphocytes (5), prothrombin index (6),healthy cells/CC (7), T1-4 (8), tumor size (9), thrombocytes/CC (10), erythrocytes/CC (11),lymphocytes/CC (12). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0). CONCLUSIONS: Optimal management for LCP are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis. Parameter Estimates:Chi2=292.44, df=13, P=0.0000, n=672 Cox Regression Parameter Estimate Standard Error Chi- square P value 95% Lower CL 95% Upper CL Hazard Ratio 95% HazardRatio Lower CL 95% HazardRatio Upper CL Histology 0.29021 0.087856 10.91150 0.000956 0.11802 0.462408 1.336711 1.125263 1.587893 G1-3 0.32570 0.089528 13.23471 0.000275 0.15023 0.501169 1.384997 1.162098 1.650649 Phase Transition Early-Invasive Cancer -1.32520 0.393120 11.36353 0.000749 -2.09570 -0.554700 0.265749 0.122984 0.574244 Adjuvant Chemoimmunoradiotherapy -1.01228 0.201036 25.35421 0.000000 -1.40630 -0.618253 0.363391 0.245048 0.538885 Phase Transition N0--N12 1.06470 0.147841 51.86362 0.000000 0.77493 1.354459 2.899959 2.170449 3.874666 Glucose -0.29033 0.081154 12.79817 0.000347 -0.44938 -0.131266 0.748020 0.638020 0.876984 Prothrombin Index 0.03002 0.006828 19.32862 0.000011 0.01664 0.043400 1.030473 1.016775 1.044356 Recalcification Time -0.00585 0.001771 10.92016 0.000951 -0.00932 -0.002381 0.994166 0.990722 0.997622 Heparin Tolerance 0.00366 0.000667 30.07778 0.000000 0.00235 0.004965 1.003665 1.002353 1.004977 Eosinophils/Cancer Cells -0.99120 0.425130 5.43595 0.019726 -1.82443 -0.157957 0.371133 0.161309 0.853887 Lymphocytes/Cancer Cells -0.17877 0.067403 7.03422 0.007997 -0.31088 -0.046660 0.836300 0.732805 0.954412 Erythrocytes (tot) -0.03803 0.017819 4.55381 0.032846 -0.07295 -0.003101 0.962688 0.929647 0.996904 Thrombocytes (tot) 0.00050 0.000191 6.81611 0.009034 0.00012 0.000872 1.000498 1.000124 1.000872 Neural Networks: n=611 Baseline Error=0.000; Area under ROC Curve=1.000; Correct Classification Rate=100% Rank Sensitivity PT Early---Invasive Cancer 1 9516 PT N0---N12 2 9479 Adjuvant Chemoimmunoradiotherapy 3 6705 Segmented Neutrophils 4 5951 Lymphocytes 5 5894 Prothrombin Index 6 5126 Healthy Cells/Cancer Cells 7 5034 T1-4 8 4255 Tumor Size 9 3525 Thrombocytes/Cancer Cells 10 2840 Erythrocytes/Cancer Cells 11 2740 Lymphocytes/Cancer Cells 12 2170 Bootstrap Simulation Rank Kendall’Tau-A P< Lymphocytes/Cancer Cells 1 -0.227 0.000 Healthy Cells/Cancer Cells 2 -0.223 0.000 Erythrocytes/Cancer Cells 3 -0.221 0.000 PT N0---N12 4 0.197 0.000 Thrombocytes/Cancer Cells 5 -0.197 0.000 Leucocytes/Cancer Cells 6 -0.188 0.000 Prothrombin Index 7 0.163 0.000 Eosinophils/Cancer Cells 8 -0.161 0.000 Monocytes/Cancer Cells 9 -0.144 0.000 Tumor Size 10 0.143 0.000 Seg.Neutrophils/Cancer Cells 11 -0.134 0.000 PT Early---Invasive Cancer 12 -0.131 0.000 T1-4 13 -0.124 0.000 Lymphocytes (tot) 14 -0.108 0.000 Erythrocytes (tot) 15 -0.117 0.000 Segmented Neutrophils (%) 16 0.109 0.000 Weight 17 -0.105 0.000 Eosinophils (tot) 18 -0.085 0.01 Lymphocytes (%) 19 -0.086 0.01 G1-3 20 0.083 0.01 ESS 21 0.082 0.01 Lymphocytes (abs) 22 -0.082 0.01 Heparin Tolerance 23 0.078 0.01 Stick Neutrophils/Cancer Cells 24 -0.077 0.01 Glucose 25 -0.072 0.01 Only Surgery 26 -0.065 0.05 Eosinophils (%) 27 -0.063 0.05 Eosinophils (abs) 28 -0.059 0.05 0 5 10 15 20 25 30 35 Lymphocytes/Cancer Cells 11.11.21.31.41.51.61.71.81.9 PT Early--Invasive Cancer 1 1 1.1 1.1 1.2 1.2 1.3 1.3 1.4 1.4 1.5 1.5 1.6 1.6 1.7 1.7 1.8 1.8 1.9 1.9 2 2 5-YearSurvival 5-YearSurvival P=0.0000 z=a+blnx+cy+d(lnx)^2+ey^2+fylnx+g(lnx)^3+hy^3+iy^2lnx+jy(lnx)^2 r^2=0.15389193 DF Adj r^2=0.13979013 FitStdErr=0.43174167 Fstat=12.145684 a=1.6730247 b=0.10714131 c=-1.559062 d=-0.054738649 e=2.0848282 f=-0.42449195 g=0.0015228759 h=-0.73551088 i=0.18814164 j=0.022282855 0 5 10 15 20 25 30 35 Lymphocytes/Cancer Cells 00.10.20.30.40.50.60.70.80.9 PT N0---N12 1 1 1.1 1.1 1.2 1.2 1.3 1.3 1.4 1.4 1.5 1.5 1.6 1.6 1.7 1.7 1.8 1.8 1.9 1.9 2 2 5-YearSurvival 5-YearSurvival P=0.0000 z=a+b/x+c/x^2+d/x^3+e/x^4+f/x^5+gy r^2=0.24088672 DF Adj r^2=0.23207446 FitStdErr=0.40792762 Fstat=31.944196 a=0.85682428 b=1.0401408 c=-1.0202475 d=0.47891711 e=-0.098874149 f=0.0071729116 g=0.37035265